Anti-tumor activity of elacestrant (RAD1901) in combination with alpelisib (BYL-719) in patient-derived xenograft models of ER plus breast cancer

被引：0
|
作者：
Sankaran, Banu
Garner, Fiona
Hattersley, Gary
Purandare, Dinesh
Bihani, Teeru
机构：
[1] Novartis, Cambridge, MA USA
[2] Radius Hlth, Waltham, MA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-04-14
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer
    Suzuki, E.
    Kotake, T.
    Nishimura, T.
    Yamaguchi, A.
    Pu, F.
    Toi, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Anti-tumor effects of dovitinib, a multi-target kinase inhibitor, in patient-derived gastrointestinal stromal tumor (GIST) xenograft models
    Gebreyohannes, Yemarshet Kelemework
    Van Looy, Thomas
    Wozniak, Agnieszka
    Wellens, Jasmien
    Li, Haifu
    Cornillie, Jasmien
    Vanleeuw, Ulla
    Vreys, Lise
    Squires, Matthew
    Rodringuez, Ana-Maria
    Debiec-Rychter, Maria
    Sciot, Raf
    Schoffski, Patrick
    CANCER RESEARCH, 2015, 75
  • [33] Anti-tumor activity of motesanib diphosphate alone and in combination with docetaxel or tamoxifen in xenograft models of human breast carcinoma
    Coxon, A.
    Bush, T.
    Belmontes, B.
    Suffran, D.
    Ona, V
    Rex, K.
    Caenepeel, S.
    Hughes, P.
    Koifnon, S.
    Radinsky, R.
    Kendall, R.
    Price, J.
    Polverino, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S77 - S77
  • [34] Validation of AAC-11-Derived Peptide Anti-Tumor Activity in a Single Graft Sezary Patient-Derived Xenograft Mouse Model
    Habault, Justine
    Thonnart, Nicolas
    Ram-Wolff, Caroline
    Bagot, Martine
    Bensussan, Armand
    Poyet, Jean-Luc
    Marie-Cardine, Anne
    CELLS, 2022, 11 (19)
  • [35] Orthotopic implantation of aggressive breast cancer achieves better engraftment and larger tumor in patient-derived xenograft models
    Okano, Maiko
    Kawaguchi, Tsutomu
    Takabe, Kazuaki
    CANCER RESEARCH, 2018, 78 (13)
  • [36] The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER plus breast cancer
    Palanisamy, Gopinath S.
    Venkateshappa, Chandregowda
    Goyal, Megha
    Barrett, Susanna A.
    Heam, Brian R.
    Daginakatte, Girish
    Aravind, A. B.
    Samiulla, D. S.
    Bera, Kalisankar
    Sangeetha, S.
    Khare, Leena
    Parisian, Alison D.
    Heerding, Dirk A.
    Ng, Raymond A.
    Harmon, Cyrus L.
    Samajdar, Susanta
    Ramachandra, Murali
    Myles, David C.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [37] Evaluation of anti-tumor efficacy of EC1456 in low-passage and pre-treated patient-derived xenograft models of triple-negative breast cancer
    Lu, Yingjuan
    Parker, Nikki L.
    Chu, Haiyan
    Pugh, Michael R.
    Rao, Satish I.
    Klein, Patrick J.
    Ritchie, Michael F.
    Myer, Lonnie D.
    Jaskowiak, Jennifer
    Leamon, Christopher P.
    CANCER RESEARCH, 2017, 77
  • [38] Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models
    Chen, Xiangheng
    Guan, Zhonghai
    Lu, Jun
    Wang, Haohao
    Zuo, Zhongkun
    Ye, Fei
    Huang, Jiangsheng
    Teng, Lisong
    JOURNAL OF CANCER, 2018, 9 (07): : 1207 - 1217
  • [39] Anti-tumor effects of the novel KIT mutant inhibitor M4205 in patient-derived gastrointestinal stromal tumor (GIST) xenograft models
    De Sutter, Luna
    Wozniak, Agnieszka
    Verreet, Jasper
    Vanleeuw, Ulla
    De Cock, Lore
    Linde, Nina
    Drechsler, Christine
    Esdar, Christina
    Sciot, Raf
    Schoffski, Patrick
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer
    Yuanqiao He
    Jiaqi Mei
    Hua Hao
    Fanrong Liu
    Yun Yi
    Chao Hu
    Fangxing Zou
    Xiongbing Lu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 6931 - 6941
12345